368 related articles for article (PubMed ID: 27789382)
1. Effects of (-)-sesamin on motor and memory deficits in an MPTP-lesioned mouse model of Parkinson's disease treated with l-DOPA.
Zhao TT; Shin KS; Kim KS; Park HJ; Kim HJ; Lee KE; Lee MK
Neuroscience; 2016 Dec; 339():644-654. PubMed ID: 27789382
[TBL] [Abstract][Full Text] [Related]
2. Gypenosides ameliorate memory deficits in MPTP-lesioned mouse model of Parkinson's disease treated with L-DOPA.
Zhao TT; Kim KS; Shin KS; Park HJ; Kim HJ; Lee KE; Lee MK
BMC Complement Altern Med; 2017 Sep; 17(1):449. PubMed ID: 28877690
[TBL] [Abstract][Full Text] [Related]
3. Gynostemma pentaphyllum Ethanolic Extract Protects Against Memory Deficits in an MPTP-Lesioned Mouse Model of Parkinson's Disease Treated with L-DOPA.
Kim KS; Zhao TT; Shin KS; Park HJ; Cho YJ; Lee KE; Kim SH; Lee MK
J Med Food; 2017 Jan; 20(1):11-18. PubMed ID: 28005447
[TBL] [Abstract][Full Text] [Related]
4. Effects of (-)-sesamin on chronic stress-induced memory deficits in mice.
Zhao TT; Shin KS; Park HJ; Kim KS; Lee KE; Cho YJ; Lee MK
Neurosci Lett; 2016 Nov; 634():114-118. PubMed ID: 27717829
[TBL] [Abstract][Full Text] [Related]
5. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
[TBL] [Abstract][Full Text] [Related]
7. Effects of gypenosides on anxiety disorders in MPTP-lesioned mouse model of Parkinson's disease.
Shin KS; Zhao TT; Choi HS; Hwang BY; Lee CK; Lee MK
Brain Res; 2014 Jun; 1567():57-65. PubMed ID: 24747613
[TBL] [Abstract][Full Text] [Related]
8. Nobiletin treatment improves motor and cognitive deficits seen in MPTP-induced Parkinson model mice.
Yabuki Y; Ohizumi Y; Yokosuka A; Mimaki Y; Fukunaga K
Neuroscience; 2014 Feb; 259():126-41. PubMed ID: 24316474
[TBL] [Abstract][Full Text] [Related]
9. Neurotoxic effects of berberine on long-term L-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
Shin KS; Choi HS; Zhao TT; Suh KH; Kwon IH; Choi SO; Lee MK
Arch Pharm Res; 2013 Jun; 36(6):759-67. PubMed ID: 23539311
[TBL] [Abstract][Full Text] [Related]
10. Nitrosative and cognitive effects of chronic L-DOPA administration in rats with intra-nigral 6-OHDA lesion.
Ramírez-García G; Palafox-Sánchez V; Limón ID
Neuroscience; 2015 Apr; 290():492-508. PubMed ID: 25644418
[TBL] [Abstract][Full Text] [Related]
11. Effects of (-)-sesamin on 6-hydroxydopamine-induced neurotoxicity in PC12 cells and dopaminergic neuronal cells of Parkinson's disease rat models.
Park HJ; Zhao TT; Lee KS; Lee SH; Shin KS; Park KH; Choi HS; Lee MK
Neurochem Int; 2015; 83-84():19-27. PubMed ID: 25747493
[TBL] [Abstract][Full Text] [Related]
12. L-Dopa restores striatal dopamine level but fails to reverse MPTP-induced memory deficits in rats.
Gevaerd MS; Miyoshi E; Silveira R; Canteras NS; Takahashi RN; Da Cunha C
Int J Neuropsychopharmacol; 2001 Dec; 4(4):361-70. PubMed ID: 11806861
[TBL] [Abstract][Full Text] [Related]
13. Melatonin enhances L-DOPA therapeutic effects, helps to reduce its dose, and protects dopaminergic neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice.
Naskar A; Prabhakar V; Singh R; Dutta D; Mohanakumar KP
J Pineal Res; 2015 Apr; 58(3):262-74. PubMed ID: 25626558
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
Shin JY; Park HJ; Ahn YH; Lee PH
J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
[TBL] [Abstract][Full Text] [Related]
15. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
[TBL] [Abstract][Full Text] [Related]
16. Trx-1 ameliorates learning and memory deficits in MPTP-induced Parkinson's disease model in mice.
Zhang X; Bai L; Zhang S; Zhou X; Li Y; Bai J
Free Radic Biol Med; 2018 Aug; 124():380-387. PubMed ID: 29960099
[TBL] [Abstract][Full Text] [Related]
17. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Gross CE; Ravenscroft P; Dovero S; Jaber M; Bioulac B; Bezard E
J Neurochem; 2003 Mar; 84(6):1246-55. PubMed ID: 12614325
[TBL] [Abstract][Full Text] [Related]
18. Modulatory effects of sesamin on dopamine biosynthesis and L-DOPA-induced cytotoxicity in PC12 cells.
Zhang M; Lee HJ; Park KH; Park HJ; Choi HS; Lim SC; Lee MK
Neuropharmacology; 2012 Jun; 62(7):2219-26. PubMed ID: 22293035
[TBL] [Abstract][Full Text] [Related]
19. The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.
Da Cunha C; Angelucci ME; Canteras NS; Wonnacott S; Takahashi RN
Cell Mol Neurobiol; 2002 Jun; 22(3):227-37. PubMed ID: 12469866
[TBL] [Abstract][Full Text] [Related]
20. Effects of acute and sub-chronic L-dopa therapy on striatal L-dopa methylation and dopamine oxidation in an MPTP mouse model of Parkinsons disease.
Smith ML; King J; Dent L; Mackey V; Muthian G; Griffin B; Charlton CG
Life Sci; 2014 Aug; 110(1):1-7. PubMed ID: 24880075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
